CD9 and colorectal carcinoma: In both cases of labeling, the amount of Meprin A(+)ENVs was more variable and higher in the group of CRC samples vs. samples from healthy donors, and in the case of anti-CD9 antibodies used for labeling, this difference reached statistical significance.